Feb 23, 2026Blood Sugar and Insulin Resistance: Supplement Protocol, Monitoring, and Evidence SummaryInsulin resistance precedes type 2 diabetes by years and independently drives cardiovascular risk, cognitive decline, and accelerated aging. Berberine, magnesium, alpha-lipoic acid, and chromium have the best evidence among supplements. This protocol integrates the strongest interventions with clear monitoring markers.
Feb 19, 2026Metabolic Syndrome: A Comprehensive Evidence-Based ProtocolMetabolic syndrome affects 1 in 3 adults and accelerates aging across every system. This protocol covers the interconnected drivers and the best-evidenced interventions for each component.
Feb 6, 2026Berberine and AMPK: Metabolic Health, Blood Sugar, Lipids, and Comparison to MetforminBerberine activates AMPK through mechanisms similar to metformin and shows comparable glucose-lowering effects in head-to-head trials. Lipid-lowering effects are also well-supported. Bioavailability is limited but DHBerberine improves absorption.
Jan 23, 2026Blood Sugar and Glycation Management: Berberine, ALA, Chromium, and CarnosineElevated blood glucose accelerates aging through glycation (AGE formation), oxidative stress, and inflammation. Berberine and alpha-lipoic acid have strong glucose-lowering evidence. Carnosine and benfotiamine target the downstream glycation process. A comprehensive protocol addresses multiple pathways.
Jan 10, 2026Alpha-Lipoic Acid: Metabolic Health, Peripheral Neuropathy, and R-ALA vs Racemic FormsAlpha-lipoic acid has the strongest evidence base in peripheral neuropathy (including diabetic neuropathy) where IV and high-dose oral formulations show consistent benefit. Metabolic effects are real but smaller.